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Abstract
Introduction: As part of the Centers for Disease Control and Prevention’s monitoring and 
evaluation activities for influenza vaccines, we examined relationships between influenza 
vaccination and selected outcomes in the 2009–2010 and 2010–2011 influenza seasons in a 
claims-based data environment.
Methods: We included patients with claims for trivalent influenza vaccine (TIV) and/or 2009 
pandemic influenza A H1N1 vaccine (H1N1) during the 2009–2010 and 2010–2011 influenza 
seasons. Patients were followed for several pre-specified outcomes identified in claims. Seizures 
and Guillain–Barré Syndrome were selected a priori for medical record confirmation. We 
estimated incidence rate ratios (IRR) using a self-controlled risk interval (SCRI) or a historical 
comparison design. Outcomes with elevated IRRs, not selected a priori for medical record review, 
were further investigated with review of claims histories surrounding the outcome date to 
determine whether the potential event could be ruled-out or attributed to other causes based on the 
pattern of medical care.
Results: In the 2009–2010 season, no significant increased risks for outcomes following H1N1 
vaccination were observed. Following TIV administration, the IRR for peripheral nervous system 
disorders and neuropathy was slightly elevated (1.07, 95% CI: 1.01–1.13). The IRR for 
anaphylaxis following TIV was 28.55 (95% CI: 3.57–228.44). After further investigation of claims 
histories, the majority of potential anaphylaxis cases had additional claims around the time of the 
event indicating alternate explanatory factors or diagnoses. In the 2010–2011 season following 
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TIV administration, a non-significant elevated IRR for anaphylaxis was observed with no other 
significant outcome findings.
Conclusion: After claims history review, we ultimately found no increased outcome risk 
following administration of 998,881 TIV and 538,257 H1N1 vaccine doses in the 2009–2010 
season, and 1,158,932 TIV doses in the 2010–2011 season.
Keywords
Vaccine safety; Claims; Influenza; H1N1
1. Introduction
Safety monitoring and evaluation are critical components of vaccination programs. While 
pre-licensure studies are important for identifying potential vaccine-associated adverse 
events (AEs), rare AEs may go unrecognized until there is widespread use of the vaccine in 
the population. This was best demonstrated by the excess number of cases of Guillain–Barré 
Syndrome (GBS) occurring during the swine influenza vaccination program in 1976 [1].
AEs following influenza vaccines have been widely studied. Although causal associations 
have not been established for many, AEs have been reported to occur in temporal association 
with influenza vaccines [2–7]. Many of these AEs have been previously identified through 
passive surveillance systems such as the Vaccine Adverse Event Reporting System as well as 
through active surveillance and observational epidemiologic studies using the Vaccine Safety 
Datalink (VSD).
As part of Centers for Disease Control and Prevention’s (CDC) ongoing monitoring and 
evaluation for influenza vaccine safety, we conducted evaluations of the relationship 
between 3 formulations of the influenza vaccine administered in the 2009–2010 and 2010–
2011 seasons and the occurrence of selected outcomes in a large health plan population in 
the United States (U.S.).
2. Methods
2.1. Data source
The source population was derived from an electronic health care database of a large U.S. 
insurer developed for research purposes. The data includes information on health plan 
enrollment, demographics, pharmacy dispensing, facility, and medical claims. The data 
undergo regular audits and quality control procedures and are updated monthly. The insurer 
checks for completeness and accuracy before the data is extracted for research, and access to 
the data conforms to applicable Health Insurance Portability and Accountability Act 
(HIPAA) policies. The insured population from which the data are drawn is geographically 
diverse and comprises approximately 4% of the U.S. population. Data relating to 
approximately 12 million individuals with both medical and pharmacy benefit coverage 
were available at the time this study was conducted. For a subset of 6 million health plan 
members in the research database, health plan administrative approval was provided to 
access patient-identifiable information for further inquiries, including medical chart review.
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2.2. Study population
This retrospective cohort study included individuals 6 months of age or older with complete 
medical and pharmacy benefits who were continuously enrolled in the health plan for at least 
9 months prior to the date of influenza vaccination. Participants must have received at least 
one influenza vaccination between September 1st and March 31st during the 2009–2010 
influenza season, 2010–2011 season, or one of the historical seasons from 2005–2006 to 
2008–2009. We identified influenza vaccinations with Current Procedural Terminology 
codes and Healthcare Common Procedure Coding System codes on health insurance claims.
For the 2009–2010 season, we conducted separate evaluations of the trivalent influenza virus 
vaccine (TIV) and 2009 pandemic influenza A H1N1 vaccines (H1N1). We created 1 cohort 
of patients who received at least one dose of TIV and another cohort of patients who 
received at least one dose of H1N1 vaccine (live attenuated or inactivated formulations). As 
this was a retrospective study, we chose to focus the analyses on TIV and either form of 
H1N1, but did not include seasonal live attenuated influenza vaccine (LAIV) in the analyses. 
Patients who received both TIV and H1N1 vaccines during the 2009–2010 season were 
included in both cohorts. For the 2010–2011 season, we included patients who received at 
least one dose of TIV. For individuals who received more than one dose of TIV (or more 
than one dose of H1N1 vaccine) during a single season, only their first vaccine dose was 
included in the analysis.
2.3. Adverse events
For each patient, pre-specified AEs were identified on the basis of specific ICD-9 codes 
through an initial screening of the claims data. These outcomes were clinically well defined, 
serious, and had previously been temporally associated with seasonal influenza vaccine or 
other pandemic influenza vaccine candidates in clinical trials (Table 1). Events based on 
diagnoses associated with inpatient, emergency department, and/or outpatient visits were 
identified during outcome-specific risk and control windows relative to the date of influenza 
vaccination. For improved specificity, an AE was considered only if it was the first event of 
its type to occur within a certain period of time, irrespective of the timing of the influenza 
vaccination. This restriction ensured that multiple events of the same type could not be 
counted for a given individual during a single observation period.
Claims-identified GBS and seizure events were chosen a priori for medical record 
confirmation, regardless of whether an elevated risk was detected during analysis of the 
health care claims. Medical record review was performed among the subset of the patient 
population with health plan administrative approval to access patient-identifying 
information. Trained research staff abstracted clinical information from medical records 
using standardized forms and also provided confirmation of the seizure events. A neurologist 
reviewed the abstracted clinical information to confirm GBS cases.
2.4. Analysis
For each of the influenza seasons, we estimated the incidence rate ratios (IRR) and 95% 
confidence intervals (CI) for each outcome following influenza vaccination. We 
implemented different analytic approaches for each pre-specified outcome depending on the 
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nature of the outcome, number of cases of that outcome, and the availability of appropriate 
self-controlled time windows.
Bell’s palsy, other cranial nerve disorders, central demyelinating disease, disorders of the 
peripheral nervous system and neuropathy, and seizures, were analyzed using the Self 
Controlled Risk Interval (SCRI) design. In the SCRI analysis, time intervals within the same 
person are used to classify the case as either in the risk or control period. The period time 
following vaccination is designated as the risk period, and time intervals before and after 
vaccination outside of the risk period are designated as the control periods. The day of 
vaccination (Day 0) was included in the risk window for AEs for which a same-day 
diagnosis was deemed biologically plausible. The incident rates for cases in the risk and 
control windows are compared to give an IRR [8,9]. The historical comparison analysis was 
conducted for ataxia, encephalitis/myelitis/transverse myelitis, hemorrhagic stroke, 
narcolepsy and cataplexy, ischemic stroke, anaphylaxis and other allergic reactions 
(including angioneurotic edema and urticaria) outcomes. Patients with seasonal influenza 
vaccination claims during the 2005–2006 through 2008–2009 influenza seasons served as 
the comparison group, with adjustment for age, sex, region, and administrative ability to 
request medical records. In both analyses, Poisson regression was used to calculate IRR and 
95% CIs. We implemented both methods when analyzing GBS due to the increased concern 
of the risk of GBS following influenza vaccination.
In all analyses, to examine any effect of the difference in populations with and without 
medical record availability, we tested for interaction, and stratified by patient age. We chose 
to stratify by ages above and below 25 years based on the recommendations for H1N1 
vaccine during the 2009–2010 season, and to keep the age groups consistent throughout the 
study [10]. For seizures, we limited analyses to cases occurring among patients aged 6–59 
months because prior studies have indicated this age group is at higher risk [11]. We 
conducted additional SCRI analyses for chart-confirmed seizures and GBS cases where 
possible.
2.5. Claims profile reviews
For AEs not selected a priori for medical record review but with an observed elevated risk in 
the claims data, we conducted claims profile review to further characterize the potential 
events in a timely manner and to determine if medical record review was warranted for 
further validation. Claims profiles provide a chronological claims history of all diagnoses, 
procedures, services, and medication dispensings and administrations surrounding the date 
of the potential claims-identified AE. Review of the claims profiles are an efficient way to 
determine whether a potential AE can be attributed to alternate causes or represent a rule-out 
diagnosis based on the pattern of medical care. If there is a possibility of a new onset event 
or the claims history is unclear, then medical record review is necessary to validate the 
outcome. This approach was taken in a previous study of seizures in pediatric patients [12].
We reviewed claims profiles to further investigate hemorrhagic stroke in the 2009–2010 and 
historical seasons, and anaphylaxis in the 2009–2010, 2010–2011, and historical seasons. 
Two reviewers reviewed claims histories ranging from 1 year before through 1 year after the 
claims-identified event date, with discrepancies resolved by a third reviewer.
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2.6. Privacy and confidentiality
This study followed the HIPAA guidelines for protection of patient confidentiality. The New 
England Institutional Review Board and affiliated Privacy Board approved the study 
protocol and granted a waiver of patient authorization to request medical records.
3. Results
3.1. H1N1: 2009–2010 influenza season
Table 2 presents the SCRI and historical comparison analyses for the claims-identified 
outcomes following administration of 538,257 doses of H1N1 vaccine in the 2009–2010 
season. No significant findings of an increased risk for claims-identified outcomes following 
H1N1 vaccination were observed.
Among patients 6–59 months, there were 14 seizure events identified in claims following 
H1N1 administration. Of those, 1 case had the medical record available for request, and it 
was not a confirmed seizure. Among the 9 GBS events identified in claims, medical records 
were available for 4 cases. 2 of the 4 cases were confirmed as Brighton level 2 GBS cases 
[13], with 1 case in the risk window and 1 in the control window.
3.2. TIV: 2009–2010 influenza season
Table 3 presents the SCRI and Poisson regression analyses for the claims-identified 
outcomes following administration of 998,881 doses of TIV in the 2009–2010 season. A 
slightly elevated IRR was observed for peripheral nervous system disorders and neuropathy 
following administration of TIV (IRR = 1.07, 95% CI: 1.01–1.13). After stratifying by age 
group, the IRR was 1.34 (95% CI: 0.95–1.90) in patients younger than 25 years and 1.06 
(95% CI: 1.00–1.12) in patients aged 25 years and older. In the historical comparison 
analysis, the IRR for claims-identified anaphylaxis following TIV administration was 28.55 
(95% CI: 3.57–228.44) when compared with the historical cohort. In patients less than 25 
years of age, the IRR for claims-identified hemorrhagic stroke following TIV was 2.37 (95% 
CI: 0.95–5.65); the risk was higher among patients with medical records available for 
request (IRR = 3.79, 95% CI: 0.87–16.49). A decreased risk of encephalitis/myelitis/
encephalomyelitis following TIV was observed (IRR = 0.28, 95% CI: 0.09–0.92). The 
profile reviews for patients with claims-identified anaphylaxis and hemorrhagic stroke cases 
are described at the end of this section.
Among patients 6–59 months, there were 28 claims-identified seizure events following TIV 
administration in the 2009–2010 season, of which 12 cases had medical records that could 
be requested. There were 8 confirmed cases, 1 in the risk window and 7 in the control 
window (IRR = 0.50, 95% CI: 0.62–4.06). Among the 18 claims-identified GBS events, 
records were available for 7 cases. 1 case of GBS was confirmed in the risk window and 
none in the control windows. The confirmed case did not meet the case definition for 
Brighton levels 1–3. However, the GBS case was confirmed by a neurologist in the medical 
record, and was considered a probable case by Brighton criteria [13].
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3.3. TIV: 2010–2011 influenza season
There were no significant findings in either the SCRI or historical comparison analyses for 
outcomes following administration of 1,158,932 doses of TIV in the 2010–2011 season. 
Although, an elevated IRR of 6.70 (95% CI: 0.60–74.74) was observed for anaphylaxis 
following TIV (Table 4).
Among patients 6–59 months, there were 25 seizure events identified in claims following 
TIV administration in the 2010–2011 season, of which 6 cases had medical records that 
could be requested. There were 4 confirmed cases, 1 confirmed in the risk window and 3 
confirmed in the control window (IRR = 1.17, 95% CI: 0.02–14.5). Among the 28 GBS 
events identified in claims, 4 events had medical records available for request. Of those, no 
cases were confirmed GBS.
3.4. Claims profile review results
Given the potential increased risks for anaphylaxis and hemorrhagic stroke identified in the 
2009–2010 season, we conducted a profile review for patients with diagnostic claims for 
hemorrhagic stroke or anaphylaxis following either TIV or H1N1 to further characterize the 
claims-identified potential events. The potential risk of anaphylaxis during the 2010–2011 
season was not statistically significant (IRR = 6.70, 95% CI: 0.60–74.74); however the 
elevated IRR supported further investigation.
Claims profile review was conducted for 11 patients with claims-identified anaphylaxis in 
the 2009–2010, 2010–2011, and 2005–2008 seasons. Patients ranged in age from 6 months 
through 64 years. Five case profiles included diagnostic claims for allergic reactions 
attributed to non-medicinal causes (e.g. food allergy). One case profile included diagnostic 
claims for an allergic reaction attributed to another medication or anesthesia. Two case 
profiles had anaphylaxis diagnosis codes associated with procedure claims or evaluation 
visits that resulted in an alternate diagnosis. One case appeared to be a miscode as the 
remainder of the profile did not contain claims indicative of a possible anaphylaxis event. 
The remaining 2 case profiles did not include diagnoses suggestive of alternate factors in the 
claims; 1 case occurred in the control window the 2009–2010 season and 1 case occurred in 
the risk window in the 2010–2011 season.
There were 12 claims-identified cases of hemorrhagic stroke in the 2009–2010 and historical 
seasons ranging in age from 6 months through 15 years. Nine case profiles included 
diagnostic claims for physical trauma or fall associated with head injury and/or epilepsy. 
Two case profiles had accompanying diagnoses representing potential alternate factors (e.g., 
neoplasm, surgical procedures). One case profile included claims consistent with a 
cerebrovascular accident or potential event with no alternative diagnoses in the claims 
profile available, which occurred in the 2008–2009 historical season.
4. Discussion
We utilized a large claims-based health system to conduct a retrospective analysis of the 
safety of influenza vaccines among a population of 12 million individuals. After claims 
profile reviews, we did not find any increased risk for the pre-specified outcomes following 
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998,881 TIV and 538,257 H1N1 vaccine doses administered in the 2009–2010 season, and 
1,158,932 TIV doses in the 2010–2011 season.
We found an elevated risk of claims-identified anaphylaxis following TIV in the 2009–2010 
season in the claims data. Another analysis using health insurance claims conducted in the 
Post-Licensure Rapid Immunization Safety Monitoring system also found an elevated risk 
for allergic reactions following TIV in the 2009–2010 season [14]. In the present study, a 
profile review of the healthcare claims suggested that 9 of the 11 potential cases had 
alternate contributory factors. Of the 2 profiles that did not have alternate contributory 
claims present, 1 case occurred in the 2009–2010 season, and 1 case occurred in the 2010–
2011 season. This equates to approximately 1 anaphylaxis case per million influenza doses, 
which is a similar estimate found in previous studies [15].
The risk of claims-identified hemorrhagic stroke was also elevated following TIV 
immunization in the 2009–2010 season. However, claims profile review suggested that only 
one case in the historical cohort was consistent with a potential stroke, and the remaining 
cases had alternate contributory factors. Thus, there is no measured risk of hemorrhagic 
stroke following 2009–2010 TIV administration. Analysis of other outcomes did not suggest 
any clinically significant safety concerns.
Although other studies, though not all, found a significant increased risk of GBS after H1N1 
vaccination [8,14], we did not find any increased risk of GBS following H1N1 influenza 
vaccination. Additionally, we did not find an increased risk of seizures following TIV 
vaccination in the 2010–2011 season as was found in a previous VSD study [11]. Medical 
record review of the subset of both GBS and seizure cases with administrative approval for 
medical record requests further decreased the IRR.
The ability to request medical records for only a portion of the population is a barrier to 
conducting vaccine safety analyses in this administrative claims database. This may 
contribute to the difference in findings between the present study and other systems, such as 
the VSD, where medical records are more readily available. However, our ability to conduct 
claims profile reviews was valuable in further investigating and characterizing potential 
signals in a timely manner where medical record review was not feasible. Additionally, there 
was a relatively low number of influenza vaccinations captured given the size of the 
population. Although this study utilized a vaccinated cohort, which eliminates the potential 
misclassification of the vaccine exposure, and had ample power for the AEs studied, capture 
of a larger proportion of could potentially influence generalizability. We were also unable to 
distinguish between live attenuated and inactivated H1N1 in the claims-based system. 
Vaccine capture and classification may vary between claims-based systems and medical 
record based systems such as the VSD. Lastly, the positive predictive value of ICD-9 codes 
varies by AE, and misclassification may occur resulting in possible type II error. This 
limitation may be present whenever ICD-9 codes are used as a proxy for AEs.
There are strengths and limitations for both the SCRI and the historical comparison methods 
used to analyze the risk of AEs following influenza vaccination. The SCRI method can 
control for individual-level confounders that are fixed over time, but not for time-varying 
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confounders such as seasonality; though more recent self-controlled methods do have this 
capability. The historical comparison method has increased statistical power by using 
multiple years of data, which is particularly useful for rare outcomes. The main limitation to 
this method is the increased risks occurring in the historical cohort have the potential to 
mask associations when used as a control; although any differences between the present 
cohort and the historical cohort would be discernible. Additionally, the safety of TIV in the 
historical seasons of the present study, 2005 through 2008, was examined in a previous VSD 
study [16], and no AEs were found to be associated with influenza vaccination.
We utilized a claims-based data source to evaluate the safety of TIV and H1N1 vaccines. We 
ultimately found no increased outcome risk following 998,881 TIV and 538,257 H1N1 
vaccine doses administered in the 2009–2010 season, and 1,158,932 TIV doses in the 2010–
2011 season. The large number of vaccines in this health plans’ database allowed for precise 
risk estimates of most outcomes, although claims profile reviews were critical in excluding 
cases with alternate explanations. This study adds to the body of evidence supporting the 
safety of influenza vaccines.
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